Zynex Reports Second Quarter 2025 Financial Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 31 2025
0mins
Should l Buy ?
Source: PRnewswire
Management Changes and Product Development: Zynex, Inc. appointed Steven Dyson as the new CEO and submitted its NiCO laser pulse oximeter to the FDA, marking significant steps in their business strategy and product innovation aimed at improving patient care.
Financial Performance Overview: The company reported a net revenue of $22.3 million for Q2 2025, down from $49.9 million in the previous year, resulting in a net loss of $20 million due to various operational challenges, including changes in insurance payments and restructuring efforts.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
